319 related articles for article (PubMed ID: 33068037)
1. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
Lynch DR; Farmer J; Hauser L; Blair IA; Wang QQ; Mesaros C; Snyder N; Boesch S; Chin M; Delatycki MB; Giunti P; Goldsberry A; Hoyle C; McBride MG; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot GR; Zesiewicz T; Meyer C
Ann Clin Transl Neurol; 2019 Jan; 6(1):15-26. PubMed ID: 30656180
[TBL] [Abstract][Full Text] [Related]
4. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
Lynch DR; Goldsberry A; Rummey C; Farmer J; Boesch S; Delatycki MB; Giunti P; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Weissfeld L; Meyer C
Ann Clin Transl Neurol; 2024 Jan; 11(1):4-16. PubMed ID: 37691319
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
Reisman SA; Gahir SS; Lee CI; Proksch JW; Sakamoto M; Ward KW
Drug Des Devel Ther; 2019; 13():1259-1270. PubMed ID: 31118567
[TBL] [Abstract][Full Text] [Related]
6. Omaveloxolone: First Approval.
Lee A
Drugs; 2023 Jun; 83(8):725-729. PubMed ID: 37155124
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
Jain P; Badgujar L; Spoorendonk J; Buesch K
Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
[TBL] [Abstract][Full Text] [Related]
8. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
Pilotto F; Chellapandi DM; Puccio H
Trends Mol Med; 2024 Feb; 30(2):117-125. PubMed ID: 38272714
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial.
Madsen KL; Buch AE; Cohen BH; Falk MJ; Goldsberry A; Goldstein A; Karaa A; Koenig MK; Muraresku CC; Meyer C; O'Grady M; Scaglia F; Shieh PB; Vockley J; Zolkipli-Cunningham Z; Haller RG; Vissing J
Neurology; 2020 Feb; 94(7):e687-e698. PubMed ID: 31896620
[TBL] [Abstract][Full Text] [Related]
10. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
[TBL] [Abstract][Full Text] [Related]
11. Omaveloxolone: potential new agent for Friedreich ataxia.
Lynch DR; Johnson J
Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
[TBL] [Abstract][Full Text] [Related]
12. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Profeta V; McIntyre K; Wells M; Park C; Lynch DR
Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study.
Qureshi MY; Patterson MC; Clark V; Johnson JN; Moutvic MA; Driscoll SW; Kemppainen JL; Huston J; Anderson JR; Badley AD; Tebben PJ; Wackel P; Oglesbee D; Glockner J; Schreiner G; Dugar S; Touchette JC; Gavrilova RH
J Inherit Metab Dis; 2021 Mar; 44(2):502-514. PubMed ID: 32677106
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
[TBL] [Abstract][Full Text] [Related]
15. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.
Drinkard BE; Keyser RE; Paul SM; Arena R; Plehn JF; Yanovski JA; Di Prospero NA
Arch Phys Med Rehabil; 2010 Jul; 91(7):1044-50. PubMed ID: 20599042
[TBL] [Abstract][Full Text] [Related]
16. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
Lynch DR; Perlman SL; Meier T
Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
[TBL] [Abstract][Full Text] [Related]
17. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
Lynch DR; Perlman S; Schadt K
Expert Rev Neurother; 2024 Mar; 24(3):251-258. PubMed ID: 38269532
[TBL] [Abstract][Full Text] [Related]
18. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.
Lynch DR; Willi SM; Wilson RB; Cotticelli MG; Brigatti KW; Deutsch EC; Kucheruk O; Shrader W; Rioux P; Miller G; Hawi A; Sciascia T
Mov Disord; 2012 Jul; 27(8):1026-33. PubMed ID: 22744651
[TBL] [Abstract][Full Text] [Related]
19. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
Subramony SH; Lynch DL
Cerebellum; 2024 Apr; 23(2):775-777. PubMed ID: 37219716
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study of interferon-
Lynch DR; Hauser L; McCormick A; Wells M; Dong YN; McCormack S; Schadt K; Perlman S; Subramony SH; Mathews KD; Brocht A; Ball J; Perdok R; Grahn A; Vescio T; Sherman JW; Farmer JM
Ann Clin Transl Neurol; 2019 Mar; 6(3):546-553. PubMed ID: 30911578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
